SEARCH:

PROSTVAC

Targeted immunotherapy candidate for combination treatment of prostate cancer


PROSTVAC is a prostate specific antigen (PSA)-targeted immunotherapy candidate which is being developed under a collaboration with the National Cancer Institute (NCI).

A number of clinical trials are ongoing, including combination trials of PROSTVAC and immune checkpoint inhibitors.

Ongoing or planned trials

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Location: USA
Read more: NCT03532217
PROSTVAC in Patients With Biochemically Recurrent Prostate Cancer
Location: USA
Read more: NCT02649439
Phase 2 Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Location: USA
Read more: NCT03315871
Phase 2 Study of Adjuvant PROSTVAC in Subjects at High Risk for Relapse After Radical Prostatectomy
Location: USA
Read more: NCT02772562
Phase 1/2 Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Location: USA
Read more: NCT02933255
Phase 2 Trial of PROSTVAC and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy
Location: USA
Read more: NCT02506114
Phase 2 Study of PROSTVAC and Docetaxel for Metastatic Castration Sensitive Prostate Cancer
Location: USA
Read more: NCT02649855